This HTML5 document contains 88 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00726/identifier/wikipedia/
n17http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00726/identifier/pharmgkb/
n25http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00726/identifier/pubchem-compound/
n6http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB00726/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00726/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00726/identifier/drugbank/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n26http://www.drugs.com/cdi/
n11http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n28http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00726/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB00726/identifier/chebi/
n29http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00726
rdf:type
n3:Drug
n3:description
Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]
n3:dosage
n25:271B4F51-363D-11E5-9242-09173F13E4C5 n25:271B4F52-363D-11E5-9242-09173F13E4C5 n25:271B4F4B-363D-11E5-9242-09173F13E4C5 n25:271B4F4C-363D-11E5-9242-09173F13E4C5 n25:271B4F4D-363D-11E5-9242-09173F13E4C5 n25:271B4F4E-363D-11E5-9242-09173F13E4C5 n25:271B4F4F-363D-11E5-9242-09173F13E4C5 n25:271B4F50-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
11-18 hrs
n3:indication
For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance
owl:sameAs
n6:DB00726 n27:DB00726
dcterms:title
Trimipramine
adms:identifier
n8:9738 n9:5382 n12:5584 n13:46507121 n14:D00394 n15:PA451791 n16:DB00726 n18:Trimipramine
n3:mechanismOfAction
Trimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
n3:packager
n17:271B4F41-363D-11E5-9242-09173F13E4C5 n17:271B4F42-363D-11E5-9242-09173F13E4C5 n17:271B4F43-363D-11E5-9242-09173F13E4C5
n3:synonym
5-[3-(dimethylamino)-2-Methylpropyl]-10,11-dihydro-5H-dibenz[b,F]azepine 5-(gamma-dimethylamino-beta-Methylpropyl)-10,11-dihydro-5H-dibenzo[b,F]azepine Sapilent Trimipramine Trimipramina RP-7162 Trimeproprimine 10,11-dihydro-N,N,beta-Trimethyl-5H-dibenz[b,F]azepine-5-propanamine Trimipraminum Trimeprimina Trimeprimine beta-Methylimipramine
n3:toxicity
Side effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting
n19:hasAHFSCode
n20:28-16-04-28
n3:proteinBinding
93%-96% (to plasma proteins)
n3:salt
n22:hasConcept
n23:M0021995
foaf:page
n11:trimipramine.htm n26:trimipramine.html n28:sur1417.shtml
n3:IUPAC-Name
n4:271B4F57-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4F5D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4F5C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4F59-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4F5A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4F5B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4F55-363D-11E5-9242-09173F13E4C5 n4:271B4F6C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4F56-363D-11E5-9242-09173F13E4C5 n4:271B4F6E-363D-11E5-9242-09173F13E4C5 n4:271B4F53-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4F54-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n29:N06AA06
n3:H-Bond-Acceptor-Count
n4:271B4F63-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4F64-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4F5E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4F5F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4F61-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4F60-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4F62-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid absorption
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
739-71-9
n3:category
n3:containedIn
n21:271B4F4A-363D-11E5-9242-09173F13E4C5 n21:271B4F44-363D-11E5-9242-09173F13E4C5 n21:271B4F45-363D-11E5-9242-09173F13E4C5 n21:271B4F48-363D-11E5-9242-09173F13E4C5 n21:271B4F49-363D-11E5-9242-09173F13E4C5 n21:271B4F46-363D-11E5-9242-09173F13E4C5 n21:271B4F47-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4F68-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4F6A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4F6B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4F6D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4F67-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4F66-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4F69-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4F58-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4F65-363D-11E5-9242-09173F13E4C5